Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves venetoclax for chronic lymphocytic leukaemia

High-power magnification of a Wright's stained peripheral blood smear showing chronic lymphocytic leukemia (CLL)

Source: Mary Ann Thompson / Wikimedia Commons

Venetoclax has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukaemia (pictured)

The US Food and Drug Administration (FDA) has approved venetoclax for the treatment of chronic lymphocytic leukaemia (CLL).

The drug will be available to patients who have already received treatment with another therapy and who carry the 17p deletion, a chromosomal abnormality found in around 20% of relapsed patients. This mutation is associated with poor prognosis and patients are usually resistant to conventional therapies.

The approval decision was based on the results of a single-arm phase II trial involving 107 patients with relapsed or refractory CLL and the 17p deletion. They received the oral drug at escalating doses from 20mg to 400mg for five weeks (to reduce the risk of tumour lysis syndrome) before continuing at the 400mg dose until disease progression or discontinuation.

Overall, 79.4% achieved partial or complete remission of the disease and, one year later, 84.7% had retained their response to the drug.

Venetoclax, marketed as Venclexta by AbbVie, works by inhibiting BCL2, a protein that is overexpressed by CLL cells and renders them resistant to apoptosis.

The drug was approved via the FDA’s accelerated approval process, which allows expedited review of drugs for serious or life-threatening conditions. The European Medicines Agency has also accepted a submission from AbbVie for a marketing authorisation, which is currently under evaluation.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201005

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • High-power magnification of a Wright's stained peripheral blood smear showing chronic lymphocytic leukemia (CLL)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.